| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3905247 | Urology | 2010 | 8 Pages |
Abstract
The landmark Prostate Cancer Prevention Trial (PCPT) generated interest in the potential health benefits and cost of reducing prostate cancer risk—specifically, the potential role of 5α-reductase inhibitors. However, the PCPT raised several unanswered questions, including the cause and significance of the increased incidence of high-grade tumors associated with finasteride. In the present study, we review the PCPT findings and unanswered questions, next steps in this field, and ongoing prostate cancer prevention trials addressing these unanswered questions. Particular emphasis is placed on the design of the second large-scale trial of a 5α-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
E. David Crawford, Gerald L. Andriole, Michael Marberger, Roger S. Rittmaster,